Monopar Therapeutics (MNPR)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized gain on investments | 102.817 | |||
| Foreign currency translation gain (loss) | -3.456 | |||
| Research and development | 1,730 | |||
| General and administrative | 1,504.295 | |||
| Total operating expenses | 3,234.295 | |||
| Loss from operations | -3,234.295 | |||
| Interest income | 780.769 | |||
| Net loss | -2,453.526 | |||
| Comprehensive loss | -2,354.165 | |||
| Basic and diluted (in dollars per share) | -0.35 | |||
| Weighted-average common shares outstanding, basic and diluted (in shares) | 6,998,000 | |||